Frequency Therapeutics Stock Performance
| KRRO Stock | 12.72 0.15 1.19% |
The firm shows a Beta (market volatility) of 4.99, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Frequency Therapeutics will likely underperform. At this point, Frequency Therapeutics has a negative expected return of -0.14%. Please make sure to confirm Frequency Therapeutics' total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if Frequency Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Frequency Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 1.19 | Five Day Return (0.31) | Year To Date Return 58.01 | Ten Year Return (98.14) | All Time Return (98.14) |
Last Split Factor 1:50 | Last Split Date 2023-11-06 |
1 | How Frequency Therapeutics Inc. Affects Rotational Strategy Timing - news.stocktradersdaily.com | 11/11/2025 |
2 | Korro Bio Downgraded by Piper Sandler to Neutral | 11/13/2025 |
3 | Korro Bio Posts Quarterly Earnings Results, Beats Expectations By 0.69 EPS | 11/14/2025 |
4 | Acquisition by Oliver Dolan of 21482 shares of Frequency Therapeutics subject to Rule 16b-3 | 12/15/2025 |
5 | Acquisition by Cerio Jeffrey of 41902 shares of Frequency Therapeutics subject to Rule 16b-3 | 12/16/2025 |
6 | Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences - FinancialContent | 01/15/2026 |
7 | Korro Bio Analyst Day KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE | 01/30/2026 |
| Begin Period Cash Flow | 173.1 M | |
| Total Cashflows From Investing Activities | -123.3 M |
Frequency | Build AI portfolio with Frequency Stock |
Frequency Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,280 in Frequency Therapeutics on November 11, 2025 and sell it today you would lose (2,008) from holding Frequency Therapeutics or give up 61.22% of portfolio value over 90 days. Frequency Therapeutics is currently does not generate positive expected returns and assumes 11.3974% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Frequency, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Frequency Therapeutics Target Price Odds to finish over Current Price
The tendency of Frequency Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 12.72 | 90 days | 12.72 | about 41.73 |
Based on a normal probability distribution, the odds of Frequency Therapeutics to move above the current price in 90 days from now is about 41.73 (This Frequency Therapeutics probability density function shows the probability of Frequency Stock to fall within a particular range of prices over 90 days) .
Frequency Therapeutics Price Density |
| Price |
Predictive Modules for Frequency Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Frequency Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Frequency Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Frequency Therapeutics is not an exception. The market had few large corrections towards the Frequency Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Frequency Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Frequency Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.63 | |
β | Beta against Dow Jones | 4.99 | |
σ | Overall volatility | 7.81 | |
Ir | Information ratio | -0.02 |
Frequency Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Frequency Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Frequency Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Frequency Therapeutics generated a negative expected return over the last 90 days | |
| Frequency Therapeutics has high historical volatility and very poor performance | |
| Frequency Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.27 M. Net Loss for the year was (83.58 M) with profit before overhead, payroll, taxes, and interest of 46 K. | |
| Frequency Therapeutics generates negative cash flow from operations | |
| Frequency Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Korro Bio Analyst Day KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE |
Frequency Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Frequency Stock often depends not only on the future outlook of the current and potential Frequency Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Frequency Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 8.9 M | |
| Cash And Short Term Investments | 126.1 M |
Frequency Therapeutics Fundamentals Growth
Frequency Stock prices reflect investors' perceptions of the future prospects and financial health of Frequency Therapeutics, and Frequency Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Frequency Stock performance.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (17.65) % | ||||
| Current Valuation | 70.56 M | ||||
| Shares Outstanding | 9.42 M | ||||
| Price To Book | 1.20 X | ||||
| Price To Sales | 16.06 X | ||||
| Revenue | 2.27 M | ||||
| Gross Profit | 46 K | ||||
| EBITDA | (88.34 M) | ||||
| Net Income | (83.58 M) | ||||
| Total Debt | 44.77 M | ||||
| Book Value Per Share | 10.54 X | ||||
| Cash Flow From Operations | (60.07 M) | ||||
| Earnings Per Share | (9.42) X | ||||
| Market Capitalization | 118.38 M | ||||
| Total Asset | 226.24 M | ||||
| Retained Earnings | (266.59 M) | ||||
| Working Capital | 116.57 M | ||||
About Frequency Therapeutics Performance
By examining Frequency Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Frequency Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Frequency Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.33) | (0.35) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (0.60) | (0.57) |
Things to note about Frequency Therapeutics performance evaluation
Checking the ongoing alerts about Frequency Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Frequency Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Frequency Therapeutics generated a negative expected return over the last 90 days | |
| Frequency Therapeutics has high historical volatility and very poor performance | |
| Frequency Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.27 M. Net Loss for the year was (83.58 M) with profit before overhead, payroll, taxes, and interest of 46 K. | |
| Frequency Therapeutics generates negative cash flow from operations | |
| Frequency Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Korro Bio Analyst Day KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE |
- Analyzing Frequency Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Frequency Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Frequency Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Frequency Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Frequency Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Frequency Therapeutics' stock. These opinions can provide insight into Frequency Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Frequency Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Frequency Stock, please use our How to Invest in Frequency Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Will Biotechnology sector continue expanding? Could Frequency diversify its offerings? Factors like these will boost the valuation of Frequency Therapeutics. Expected growth trajectory for Frequency significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Frequency Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Frequency Therapeutics requires distinguishing between market price and book value, where the latter reflects Frequency's accounting equity. The concept of intrinsic value - what Frequency Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Frequency Therapeutics' price substantially above or below its fundamental value.
Understanding that Frequency Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Frequency Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Frequency Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.